BioSante Pharmaceuticals, Inc. BPAX
As we’ve stated all along, this stock is on our radar at least until Feb. 14th, the long awaited FDA date. There still appears to be a large gap to fill on the chart up to the 2.00 range. Even if BPAX were only to recover half of what was lost on the gap-down, we’d still observe an added 50% in gains from this vantage.
Atrinsic, Inc. ATRN
So long as we continue to see these chances offered up by this stock, we will leave it on our tickers. Thus far it has been a trader’s paradise.
North Springs Resources Corp. NSRS
It is always a good idea to remain on your guard with a big gainer like this. People often tend to get greedy when a stock is enjoying such a protracted uptrend, but protecting profits is paramount, and thus it may be time to consider our exit strategy before this party comes to a close.